Rare Disease Biotech Nabs $400M In Financing
Amicus Therapeutics, a biotechnology company in commercial and developmental stages for its various planned treatments for genetic disorders, said Friday it had raised $400 million in credit financing from a British...To view the full article, register now.
Already a subscriber? Click here to view full article